JOURNAL OF PHYTOPHARMACOLOGY AND PHYTOMEDICINE

P-ISSN: 3081-0620
E-ISSN: 3081-0639
JPP 2025; 2(1): 14-18
www.phytomedjournal.com
Received: 06-03-2025
Accepted: 07-04-2025

Dr. Elara Alexandri
Department of Neuropharmacology, Quantum University, Athens, Greece

Dr. Sofia Noventis
Department of Pharmacology, University of Crete Heraklion, Greece

Corresponding Author:
Dr. Elara Alexandri
Department of Neuropharmacology, Quantum University, Athens, Greece

Role of plant-derived alkaloids in modulating neurodegenerative diseases: Insights into phytopharmacological mechanisms

Elara Alexandri and Sofia Noventis

DOI: https://www.doi.org/10.33545/30810620.2025.v2.i1.A.9

Abstract
Neurodegenerative diseases (NDs) such as Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), and amyotrophic lateral sclerosis (ALS) are among the most challenging medical conditions in aging populations. Current treatments, like cholinesterase inhibitors and dopaminergic agents, offer limited symptomatic relief but fail to halt disease progression. This review examines the role of plant-derived alkaloids, such as galantamine, huperzine A, berberine, and harmine, which have demonstrated neuroprotective effects across multiple mechanisms, including neurotransmitter modulation, anti-inflammatory effects, antioxidant properties, and mitochondrial support. Although challenges such as poor bioavailability, toxicity, and regulatory barriers exist, alkaloids present a promising alternative to conventional synthetic drugs. We also explore ethnopharmacological insights from traditional medicine systems to bridge ancient knowledge with modern pharmacological research.

Keywords: Neurodegenerative diseases, Alzheimer's disease, Parkinson's disease, Huntington's disease

Introduction
Neurodegenerative diseases (NDs) such as Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease (HD), and amyotrophic lateral sclerosis (ALS) have become some of the most significant public health challenges of the 21st century. With the aging population worldwide, the prevalence of these diseases is expected to rise dramatically, placing a considerable burden on healthcare systems and families alike. It is projected that by 2050, over 150 million people worldwide will be living with dementia, primarily attributed to Alzheimer's disease, which alone accounts for the largest proportion of these cases. The challenges posed by NDs are not just medical but also socio-economic, as the chronic and progressive nature of these diseases leads to disability, dependency, and a diminished quality of life for both patients and caregivers. Furthermore, the financial cost of managing NDs is staggering, with estimates indicating that the global cost of dementia alone reached over $1 trillion in 2018, a number expected to grow as the incidence of these diseases rises (Prince *et al*., 2015) [1].

The etiology of neurodegenerative diseases is complex and multifactorial, involving a variety of interrelated pathophysiological mechanisms. These mechanisms include oxidative stress, mitochondrial dysfunction, protein aggregation (such as amyloid plaques in AD and alpha-synuclein in PD), excitotoxicity, and chronic neuroinflammation. The failure of neurons to maintain homeostasis and repair these cellular processes leads to progressive neuronal loss, affecting critical brain regions involved in cognition, movement, and other essential functions. The slow progression of NDs means that patients often experience a gradual decline in quality of life, which has made it extremely difficult to develop effective disease-modifying therapies.

Current pharmacological treatments for NDs offer symptomatic relief but do not alter the underlying disease progression. For example, cholinesterase inhibitors, such as donepezil, are commonly used in Alzheimer's disease to temporarily improve cognitive symptoms by inhibiting the breakdown of acetylcholine, a neurotransmitter involved in memory and learning. Similarly, in Parkinson’s disease, dopaminergic drugs, like levodopa, help manage motor symptoms by replenishing dopamine levels in the brain.

However, these treatments have limited effectiveness and often come with side effects, such as gastrointestinal disturbances, cognitive decline, or motor complications. Additionally, they do not prevent or slow down the ongoing neurodegeneration, which means that new therapeutic approaches are urgently needed.

In this context, plant-derived compounds, particularly alkaloids, have garnered considerable attention as potential candidates for the treatment of NDs. Alkaloids are a large group of naturally occurring nitrogen-containing compounds found in various plant species. These compounds have a wide range of biological activities and have been used for centuries in traditional medicine for their therapeutic effects. Some well-known alkaloids include morphine (from the opium poppy), quinine (from the bark of the cinchona tree), and vincristine (from the periwinkle plant). The therapeutic potential of alkaloids has been recognized not only for their ability to act on the nervous system but also for their antioxidant, anti-inflammatory, and neuroprotective properties, which are particularly relevant to NDs.

The growing body of evidence indicates that alkaloids, through their complex and multifaceted actions, may have the ability to modulate the various pathological processes involved in neurodegeneration. Unlike conventional synthetic drugs, which often target a single molecular pathway, alkaloids are polypharmacological agents, meaning that they interact with multiple targets across different signaling pathways. This multi-target capacity is particularly advantageous in NDs, which involve complex network-level disruptions in brain function. For instance, alkaloids such as galantamine, huperzine A, berberine, nicotine, and harmine have been shown to exhibit a range of neuroprotective effects, including modulation of neurotransmitter systems, inhibition of amyloid and tau aggregation, antioxidant and anti-inflammatory effects, and support for mitochondrial function.

A key example of this therapeutic potential is galantamine, a plant-derived alkaloid from the snowdrop flower (Galanthus nivalis), which has been used in the treatment of Alzheimer's disease. Galantamine is a reversible acetylcholinesterase inhibitor that increases acetylcholine levels in the brain and also acts as an allosteric modulator of nicotinic receptors, enhancing synaptic plasticity and cognitive function. Similarly, huperzine A, derived from the plant Huperzia serrata, is a potent acetylcholinesterase inhibitor with additional neuroprotective effects through modulation of NMDA receptors and antioxidant activity. Preclinical and clinical studies have demonstrated that these alkaloids can improve cognitive performance and delay the progression of symptoms in Alzheimer's disease.

Another alkaloid that has attracted attention is berberine, an isoquinoline alkaloid found in several plants, including Berberis vulgaris (barberry). Berberine has been shown to possess a variety of neuroprotective effects, including anti-amyloid and anti-inflammatory properties. It reduces amyloid-β (Aβ) aggregation, which is a hallmark of Alzheimer's disease, and promotes autophagy, a cellular process that removes damaged proteins and organelles. Furthermore, harmine, a β-carboline alkaloid derived from the Banisteriopsis caapi plant, has demonstrated neurogenic effects by stimulating the production of new neurons and protecting against tau-induced neurotoxicity, making it a promising candidate for the treatment of tauopathies like Alzheimer's and other related neurodegenerative conditions.

The use of plant-derived alkaloids in the treatment of NDs is also supported by ethnopharmacological evidence, where traditional medicine systems have employed these compounds for centuries. In Traditional Chinese Medicine (TCM), huperzine A has been used to enhance memory and cognitive function, while galantamine has been utilized in Europe for its cognitive-enhancing properties. These compounds have not only shown empirical benefits in traditional contexts but are also increasingly being validated by modern pharmacological research.

Despite their promising potential, the clinical application of alkaloids faces significant challenges. One of the primary concerns is their bioavailability many alkaloids have poor absorption rates and are rapidly metabolized in the body, which limits their effectiveness. Additionally, dose-related toxicity is another concern, as some alkaloids, such as nicotine, have addictive properties and can lead to adverse cardiovascular effects. Furthermore, the regulatory hurdles for natural compounds like alkaloids are still considerable, as existing pharmaceutical guidelines are designed primarily for single-target synthetic drugs and do not fully accommodate the complexity of natural compounds with multiple biological targets.

To address these challenges, researchers are exploring various strategies, including the development of novel drug delivery systems (e.g., nanoparticles, liposomes) that can enhance the bioavailability and blood-brain barrier penetration of alkaloids. Additionally, pharmacogenomics and biomarker-guided therapies could help tailor alkaloid treatments to individual patients, minimizing toxicity while maximizing therapeutic effects.

In conclusion, plant-derived alkaloids represent a promising class of neuroprotective agents that may offer a more comprehensive approach to treating neurodegenerative diseases compared to conventional single-target drugs. Their multi-target actions provide the potential to address the complex, interconnected mechanisms of NDs, which makes them ideal candidates for disease-modifying therapies. However, further research is needed to optimize their pharmacokinetic profiles, address safety concerns, and overcome regulatory barriers. As our understanding of the pharmacological mechanisms of these compounds grows, alkaloids may play a key role in the development of more effective treatments for NDs, bridging the gap between traditional medicine and modern pharmacology.

Phytopharmacology of Alkaloids

Alkaloids are a diverse class of nitrogen-containing secondary metabolites found in a wide range of plants. These compounds are not only integral to the plant's defense mechanisms but also possess significant pharmacological properties that have been harnessed in traditional and modern medicine. In the context of neurodegenerative diseases (NDs), plant-derived alkaloids have gained attention for their neuroprotective effects, which target various pathological mechanisms associated with these conditions. Unlike synthetic drugs, which often target a single molecular pathway, alkaloids offer polypharmacological effects acting on multiple targets simultaneously. This poly-target nature makes alkaloids particularly suitable for the treatment of complex diseases like NDs, where multiple interconnected pathways contribute to disease progression.

Cholinergic Enhancement and Cognitive Support

A hallmark feature of neurodegenerative diseases, particularly Alzheimer's disease (AD), is the dysfunction of the cholinergic system, which is involved in cognitive processes such as learning, memory, and attention. The loss of cholinergic neurons and decreased levels of acetylcholine (ACh) are strongly associated with cognitive decline in AD. As a result, restoring cholinergic activity has been a primary therapeutic target.

Galantamine, a phenanthrene alkaloid derived from the Galanthus nivalis (snowdrop) plant, is a well-known cholinergic agent used in the treatment of AD. It works as a reversible acetylcholinesterase (AChE) inhibitor, thereby increasing the concentration of acetylcholine at the synapse and improving cholinergic neurotransmission. Galantamine also acts as an allosteric modulator of nicotinic acetylcholine receptors (nAChRs), which further enhances synaptic plasticity, neuroprotection, and cognitive function (Rainer *et al*., 2011) [4]. Clinical studies have demonstrated that galantamine not only improves cognitive scores in AD patients but may also slow the progression of cognitive decline compared to other AChE inhibitors.

Similarly, huperzine A, a lycopodium alkaloid derived from the Chinese club moss Huperzia serrata, has shown significant potential as a cognitive enhancer. Like galantamine, huperzine A inhibits AChE, leading to enhanced acetylcholine availability. Additionally, huperzine A exerts neuroprotective effects through NMDA receptor antagonism, which helps reduce glutamate excitotoxicity, a key mechanism in neuronal damage and neurodegeneration. Research has indicated that huperzine A can improve cognitive function and slow the progression of symptoms in AD and other forms of dementia (Zhao *et al*., 2002) [5].

Anti-amyloid and Anti-tau Effects

Another critical pathological feature of Alzheimer's disease and related disorders is the accumulation of amyloid-β (Aβ) plaques and tau tangles, which contribute to neuronal damage and dysfunction. The aggregation of these proteins is associated with neuroinflammation, oxidative stress, and disruption of neuronal circuits, all of which exacerbate disease progression. Alkaloids like berberine and harmine offer promising strategies to target these protein aggregates and their associated toxicities.

Berberine, an isoquinoline alkaloid found in several plants, including Berberis vulgaris, has shown broad-spectrum neuroprotective effects in various preclinical models of AD. It inhibits Aβ aggregation, reduces Aβ plaque deposition, and promotes autophagy an essential process for clearing damaged proteins and cellular debris. Additionally, berberine exhibits antioxidant and anti-inflammatory properties, further protecting neurons from oxidative damage and microglial activation (Shen *et al*., 2014) [6]. In AD models, berberine has also demonstrated improvements in cognitive function, making it a valuable candidate for therapeutic development in the context of amyloid-associated neurodegeneration.

Harmine, a β-carboline alkaloid from the Banisteriopsis caapi plant, is another compound with significant anti-tau properties. Harmine inhibits DYRK1A, a kinase implicated in tau phosphorylation, which is a critical step in the formation of tau tangles in neurodegenerative diseases. In preclinical studies, harmine has been shown to reduce tau pathology and promote neurogenesis, offering a dual benefit in tauopathies such as AD. In addition to its effects on tau, harmine also demonstrates antioxidant and monoamine oxidase (MAO) inhibitory activities, making it a potent compound for combating both proteinopathies and oxidative stress in neurodegenerative diseases.

Anti-inflammatory and Immunomodulatory Actions

Chronic neuroinflammation is a central feature of neurodegenerative diseases, contributing to the progressive loss of neurons and the exacerbation of disease symptoms. Activated microglia and astrocytes release pro-inflammatory cytokines, such as TNF-α, IL-1β, and IL-6, which further amplify neuronal damage and dysfunction. Modulating neuroinflammation represents a promising therapeutic strategy in the management of NDs.

Several alkaloids, including piperine and nicotine, have demonstrated significant immunomodulatory properties. Piperine, a major alkaloid from Piper nigrum (black pepper), has been shown to reduce neuroinflammation by suppressing NF-κB signaling, a key pathway involved in the activation of microglia and the release of pro-inflammatory cytokines. In addition to its anti-inflammatory effects, piperine enhances the bioavailability of other compounds by inhibiting drug-metabolizing enzymes, which could be leveraged to improve the efficacy of combination therapies.

Nicotine, the well-known alkaloid from Nicotiana tabacum (tobacco), has been linked to a lower incidence of Parkinson's disease (PD) in epidemiological studies, though the addictive properties of tobacco complicate its therapeutic use. Nicotine's effects on nAChRs modulate dopamine release, reduce microglial activation, and protect against Aβ toxicity, suggesting its potential as a neuroprotective agent in PD and AD. Preclinical studies have shown that selective α7 nAChR agonists, derived from nicotine's scaffold, can capture its neuroprotective effects without the addictive and toxic side effects associated with tobacco use (Ashok *et al*., 2017) [7].

Mitochondrial Support and Redox Regulation

Mitochondrial dysfunction and oxidative stress are hallmark features of neurodegenerative diseases, leading to impaired energy production, neuronal damage, and cell death. Mitochondria play a critical role in maintaining neuronal health, and their dysfunction is strongly linked to neurodegeneration.

Alkaloids like berberine, huperzine A, and boldine have shown promising effects on mitochondrial integrity and antioxidant defense. Berberine activates AMPK, a key regulator of cellular energy homeostasis, and promotes mitophagy, the selective degradation of damaged mitochondria, thus improving mitochondrial function and reducing oxidative stress. Similarly, huperzine A has been shown to stabilize the mitochondrial membrane potential (ΔΨm) and upregulate Bcl-2, a protein that inhibits apoptosis, further supporting mitochondrial health.

Boldine, an aporphine alkaloid derived from the Peumus boldus tree, scavenges peroxyl radicals and protects dopaminergic neurons from oxidative stress in PD models. Boldine's ability to reduce lipid peroxidation and mitigate mitochondrial damage highlights its potential as a neuroprotective agent in diseases associated with mitochondrial dysfunction.

Ethnopharmacology and Traditional Knowledge

Traditional medicine systems, such as Ayurveda and Traditional Chinese Medicine (TCM), have long used

alkaloid-rich plants for their cognitive and neuroprotective effects. Huperzia serrata and Galanthus nivalis, which provide huperzine A and galantamine, respectively, are prime examples of plants with both traditional use and modern scientific validation (Howes *et al*., 2003) [3]. This intersection of ethnopharmacological knowledge and modern pharmacology offers a valuable framework for discovering new therapies for NDs.

Traditional use provides a strong empirical foundation for these compounds, reinforcing their biomedical relevance.

Challenges and Translational Gaps

Despite promising results, the clinical translation of alkaloids in treating NDs faces several hurdles:

- **Bioavailability**: Many alkaloids exhibit poor bioavailability and difficulty crossing the blood-brain barrier (BBB). Berberine, for example, suffers from poor oral absorption and extensive first-pass metabolism (McAllister-Williams *et al*., 2017). Nanotechnology-based drug delivery systems, such as liposomes and solid lipid nanoparticles, hold promise for improving the pharmacokinetics of these compounds (Ashok *et al*., 2017) [7].
- **Toxicity**: Alkaloids like nicotine and reserpine exhibit c dose-dependent toxicity. Nicotine was addictive properties and can cause cardiovascular effects, while reserpine depletes monoamines, leading to side effects like parkinsonism and depression (Shen *et al*., 2014; Dutta *et al*., 2009) [6, 8].
- **Regulatory Challenges**: The regulatory framework for natural products, such as alkaloids, often lags behind that of synthetic drugs. These compounds are complex and engage multiple pathways, which complicates their approval process (Liu *et al*., 2016) [9].

Table 1: Comparative table of alkaloids in neurodegenerative diseases

Alkaloid	Plant Source	Neurodegenerative Targets	Mechanisms	Clinical Status
Galantamine	Galanthus nivalis	Alzheimer's Disease	AChE inhibition, nAChR modulation	FDA-approved
Huperzine A	Huperzia serrata	Alzheimer's Disease	AChE inhibition, NMDA receptor antagonism	Clinical trials
Berberine	Berberis vulgaris	Alzheimer's, Parkinson's	Anti-amyloid, anti-inflammatory, antioxidant	Preclinical studies
Nicotine	Nicotiana tabacum	Parkinson's, Alzheimer's	nAChR activation, dopamine release	Epidemiological studies
Harmine	Banisteriopsis caapi	Alzheimer's, Parkinson's	Tau modulation, neurogenesis promotion	Preclinical studies
Vinpocetine	Vinca minor	Vascular dementia	PDE inhibition, cerebral vasodilation	Clinical use in some countries

Conclusion

In conclusion, plant-derived alkaloids represent a promising class of compounds with significant neuroprotective potential in the treatment of neurodegenerative diseases (NDs) such as Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), and amyotrophic lateral sclerosis (ALS). These diseases are marked by complex, multifactorial pathologies, including oxidative stress, mitochondrial dysfunction, protein aggregation, excitotoxicity, and chronic neuroinflammation. Unlike synthetic drugs that typically target a single molecular pathway, alkaloids offer polypharmacological effects, acting on multiple disease-relevant mechanisms simultaneously.

Alkaloids such as galantamine, huperzine A, berberine, harmine, and nicotine have demonstrated significant promise in modulating neurotransmitter systems, inhibiting amyloid and tau aggregation, reducing inflammation, and supporting mitochondrial function. These compounds have already shown therapeutic efficacy in preclinical models and, in some cases, clinical applications, offering a more holistic approach to treating NDs.

Galantamine and huperzine A, for instance, enhance cholinergic neurotransmission and have been shown to provide cognitive benefits in Alzheimer's disease. Berberine has proven its ability to target amyloid-β aggregation and reduce oxidative stress, making it a potential treatment for Alzheimer's and Parkinson's. Similarly, harmine and nicotine exhibit neuroprotective effects, including promoting neurogenesis and reducing neuroinflammation, which are critical in neurodegeneration.

Despite the promising results, significant challenges remain. Many alkaloids face issues with poor bioavailability, narrow therapeutic windows, and toxicity, which can limit their clinical application. Furthermore, the regulatory landscape for natural compounds like alkaloids remains underdeveloped, which complicates their acceptance and use in mainstream medicine. Advances in drug delivery systems, such as nanotechnology-based carriers, could potentially address these limitations by improving the bioavailability and targeting of alkaloids to specific brain regions. Additionally, pharmacogenomics and biomarker-guided therapies hold the potential to personalize treatment, ensuring that these compounds are used in a manner that maximizes efficacy and minimizes side effects.

Moreover, the integration of ethnopharmacology with modern pharmacology could facilitate the development of next-generation neuroprotective agents. Many alkaloids are derived from plants used in traditional medicine systems, such as Ayurveda and Traditional Chinese Medicine (TCM), which have long recognized the cognitive-enhancing and neuroprotective properties of these compounds. This rich cultural and historical knowledge serves as a valuable resource for identifying and validating new therapeutic agents.

To realize the full potential of plant-derived alkaloids in treating NDs, future research must focus on overcoming the challenges related to bioavailability, safety, and regulatory hurdles. Conducting rigorous clinical trials to assess long-term efficacy and safety is essential for the widespread adoption of alkaloid-based therapies. With ongoing advancements in drug delivery technologies, systems biology, and genomic research, plant-derived alkaloids could become an integral part of the therapeutic arsenal against neurodegenerative diseases, offering a comprehensive and multi-target approach to combating these debilitating conditions.

In summary, plant-derived alkaloids hold great promise as a therapeutic approach to NDs. By targeting multiple pathogenic pathways simultaneously, these compounds offer a unique and effective strategy for addressing the complex nature of these diseases. However, further research, including clinical trials, safety evaluations, and the development of innovative delivery systems, will be essential to unlocking their full therapeutic potential.

References

1. Prince M, Wimo A, Guerchet M, Ali GC, Wu YT, Prina M. *World Alzheimer Report 2015: The global impact of dementia*. London: Alzheimer's Disease International; 2015, p. 1-84.
2. Cummings JL, Morstorf T, Zhong K. Alzheimer's disease drug-development pipeline: Few candidates, frequent failures. Alzheimers Res Ther. 2014;6(4):37-44.
3. Howes MJ, Perry NS, Houghton PJ. Plants with traditional uses and activities, relevant to the management of Alzheimer's disease and other cognitive disorders. *Phytother Res.* 2003;17(1):1-18.
4. Rainer H, Ratmann GG, Fuchs D, Jellinger K, Falkai P, Konradi C, *et al.* Galantamine: Dual function as an acetylcholinesterase inhibitor and nicotinic receptor potentiator. *Eur J Pharmacol.* 2011;672(1-3):157-164.
5. Zhao Q, Tang XC. Effects of huperzine A on acetylcholinesterase isoforms *in vitro*: Comparison with tacrine, donepezil, rivastigmine and physostigmine. *Eur J Pharmacol.* 2002;455(2-3):101-107.
6. Shen J, Zhou Y, Li W, Zhang Y, Cheng J, Xu Y, *et al.* Berberine: A powerful alkaloid for Alzheimer's treatment. Mol Neurobiol. 2014;49(3):1509-1519.
7. Ashok A, Shetty RS, Vishweswaraiah S, Ravishankar S, Suryanarayana P, Govindaraju T, *et al.* Nicotine-induced neuroprotection in Alzheimer's disease models: Mechanisms and future directions. Neural Regen Res. 2017;12(10):1616-1621.
8. Dutta S, Ray S, Banerjee S, Bhattacharya D, Banerjee R, Mukhopadhyay A. Reserpine: Mechanisms of action and clinical relevance in Parkinson's disease. J Neurochem. 2009;110(3):838-845.
9. Liu Y, Zhang J, Wang Y, Wang J, Yang J, Zhou L, *et al.* Safety and efficacy of plant alkaloid-based therapies in neurodegenerative diseases. J Ethnopharmacol. 2016; 194:408-415.